AU2005237788A1 - Indole and azaindole derivatives with antitumor action - Google Patents

Indole and azaindole derivatives with antitumor action Download PDF

Info

Publication number
AU2005237788A1
AU2005237788A1 AU2005237788A AU2005237788A AU2005237788A1 AU 2005237788 A1 AU2005237788 A1 AU 2005237788A1 AU 2005237788 A AU2005237788 A AU 2005237788A AU 2005237788 A AU2005237788 A AU 2005237788A AU 2005237788 A1 AU2005237788 A1 AU 2005237788A1
Authority
AU
Australia
Prior art keywords
dimethoxy
indole
phenyl
methoxyphenyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005237788A
Other languages
English (en)
Inventor
Paolo Celestini
Carlo Farina
Stefania Gagliardi
Paola Misiano
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
NiKem Research SRL
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
NiKem Research SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, NiKem Research SRL filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Publication of AU2005237788A1 publication Critical patent/AU2005237788A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
AU2005237788A 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action Abandoned AU2005237788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000874A ITMI20040874A1 (it) 2004-04-30 2004-04-30 Derivati indolici ed azaindolici con azione antitumorale
ITMI2004A000874 2004-04-30
PCT/EP2005/051908 WO2005105213A2 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Publications (1)

Publication Number Publication Date
AU2005237788A1 true AU2005237788A1 (en) 2005-11-10

Family

ID=34968098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005237788A Abandoned AU2005237788A1 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Country Status (7)

Country Link
US (1) US20070248672A1 (https=)
EP (1) EP1750687A2 (https=)
JP (1) JP2007535520A (https=)
AU (1) AU2005237788A1 (https=)
CA (1) CA2564249A1 (https=)
IT (1) ITMI20040874A1 (https=)
WO (1) WO2005105213A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
EP2134176A4 (en) * 2007-03-30 2012-08-29 Brigham & Womens Hospital COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
CN102791688B (zh) * 2009-10-07 2014-11-12 卡罗生物股份公司 雌激素受体配体
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
SI2825541T1 (sl) 2012-03-16 2016-10-28 Vitae Pharmaceuticals, Inc. Modulatorji jetrnega receptorja X
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
ES2734479T3 (es) * 2012-09-21 2019-12-10 Vivolux Ab Medios y métodos para tratar tumores sólidos
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
WO2014173901A1 (en) * 2013-04-23 2014-10-30 Laboratorios Del Dr. Esteve, S.A. PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
EP3766885B1 (en) 2015-06-17 2022-05-25 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
US11866409B2 (en) 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
RS67557B1 (sr) 2018-08-24 2026-01-30 Pharmacosmos Holding As Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US12404261B2 (en) * 2020-12-22 2025-09-02 Novartis Ag Compounds and compositions for treating conditions associated with cGAS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105140A (en) * 1870-07-05 Improvement in cigar-wrapping machines
DE2005845A1 (de) * 1969-02-12 1970-09-03 Sumitomo Chemical Company, Ltd., Osaka (Japan) Verfahren zur Herstellung von Benzodiazepinen und ihren Salzen
AR205437A1 (es) * 1972-09-25 1976-05-07 Hoffmann La Roche Procedimiento para la preparacion de derivados de indoloquinolinona
CA1012147A (en) * 1972-09-25 1977-06-14 Hoffmann-La Roche Limited Indolo quinoline derivatives
US4225711A (en) * 1978-10-02 1980-09-30 Schering Corporation Substituted 2-[(methylsulfinyl)acetyl]-3-heterocyclicindoles and their use as immunosuppressants
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
GB9319100D0 (en) * 1993-09-15 1993-11-03 Pfizer Ltd 3-(3-pyridinyl)h-indoles
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
WO2002102301A2 (en) * 2000-12-07 2002-12-27 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP4279561B2 (ja) * 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles

Also Published As

Publication number Publication date
EP1750687A2 (en) 2007-02-14
US20070248672A1 (en) 2007-10-25
WO2005105213A2 (en) 2005-11-10
CA2564249A1 (en) 2005-11-10
JP2007535520A (ja) 2007-12-06
ITMI20040874A1 (it) 2004-07-30
WO2005105213A3 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
AU2005237788A1 (en) Indole and azaindole derivatives with antitumor action
TWI306860B (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
EP3154957B1 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
ES2819448T3 (es) Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
CN105452257B (zh) 新型稠合嘧啶化合物或其盐
CN102307870B (zh) Vegf-r2的吡啶氧基吲哚类抑制剂及其用于治疗疾病的用途
CN102686591B (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2829539B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
Biersack et al. Indole compounds against breast cancer: recent developments
JP5425060B2 (ja) ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
Baytas Recent advances in combretastatin A-4 inspired inhibitors of tubulin polymerization: an update
WO2021057867A1 (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
CN103237799A (zh) 杂环衍生物、制备方法及其药学用途
JP2005511540A (ja) インドリノン化合物を用いる急性骨髄性白血病の治療
JP2006508981A (ja) 癌を治療するためのインドリノンと化学療法剤との組み合わせ投与
US8153630B2 (en) Kinase inhibitors
TW201339150A (zh) 新穎哌啶化合物或其鹽
EP3632443A1 (en) Anti-tumor effect potentiator using novel biphenyl compound
AU2010333083B2 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
CA3233398A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
CN109310672B (zh) σ受体配体在癌症中的用途
WO2024121256A1 (en) Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
HK40065706A (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
HK40065706B (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
HK1198164B (en) 3,5-disubstituted alkynylbenzene compound and salt thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application